Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 9033 entries
Sorted by: Best Match Show Resources per page
Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence.

Surgical case reports

Adachi Y, Kikumori T, Miyajima N, Inaishi T, Onishi E, Shibata M, Nakanishi K, Takeuchi D, Hayashi H, Kodera Y.
PMID: 26943450
Surg Case Rep. 2015 Dec;1(1):126. doi: 10.1186/s40792-015-0128-z. Epub 2015 Dec 30.

Cancer antigen 15-3 (CA15-3) is considered as a marker for breast cancer recurrence. However, we encountered a case where the patient showed postoperative elevation of the CA15-3 level due to pernicious anemia without evidence of breast cancer recurrence. The...

Cite
Adachi Y, Kikumori T, Miyajima N, et al. Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surg Case Rep. 2015;1(1):126doi: 10.1186/s40792-015-0128-z.
Adachi, Y., Kikumori, T., Miyajima, N., Inaishi, T., Onishi, E., Shibata, M., Nakanishi, K., Takeuchi, D., Hayashi, H., & Kodera, Y. (2015). Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surgical case reports, 1(1), 126. https://doi.org/10.1186/s40792-015-0128-z
Adachi, Yayoi, et al. "Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence." Surgical case reports vol. 1,1 (2015): 126. doi: https://doi.org/10.1186/s40792-015-0128-z
Adachi Y, Kikumori T, Miyajima N, Inaishi T, Onishi E, Shibata M, Nakanishi K, Takeuchi D, Hayashi H, Kodera Y. Postoperative elevation of CA15-3 due to pernicious anemia in a patient without evidence of breast cancer recurrence. Surg Case Rep. 2015 Dec;1(1):126. doi: 10.1186/s40792-015-0128-z. Epub 2015 Dec 30. PMID: 26943450; PMCID: PMC4696936.
Copy Download .nbib Format: NLM
Acitretin : A Review of its Pharmacology and Therapeutic Use.

Drugs

Pilkington T, Brogden RN.
PMID: 28421560
Drugs. 1992 Apr;43(4):597-627. doi: 10.2165/00003495-199243040-00010.

SYNOPSIS: Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy...

Cite
Pilkington T, Brogden RN. Acitretin : A Review of its Pharmacology and Therapeutic Use. Drugs. 1992;43(4):597-627doi: 10.2165/00003495-199243040-00010.
Pilkington, T., & Brogden, R. N. (1992). Acitretin : A Review of its Pharmacology and Therapeutic Use. Drugs, 43(4), 597-627. https://doi.org/10.2165/00003495-199243040-00010
Pilkington, Tania, and Brogden, Rex N. "Acitretin : A Review of its Pharmacology and Therapeutic Use." Drugs vol. 43,4 (1992): 597-627. doi: https://doi.org/10.2165/00003495-199243040-00010
Pilkington T, Brogden RN. Acitretin : A Review of its Pharmacology and Therapeutic Use. Drugs. 1992 Apr;43(4):597-627. doi: 10.2165/00003495-199243040-00010. PMID: 28421560.
Copy Download .nbib Format: NLM
Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors.

Oncotarget

Cheng Y, Wang S, Han L, Liu P, Li H, Ren X, Yu J, Hao X.
PMID: 28978153
Oncotarget. 2017 Aug 07;8(40):68746-68757. doi: 10.18632/oncotarget.19975. eCollection 2017 Sep 15.

To demonstrate the mutational profiles in solid tumors, we profiled 165 solid tumor samples, including 9 cancer types and 4 sample types, by using amplicon-based next-generation sequencing panel covering 48 highly mutated tumorigenesis-related genes that were deep sequenced at...

Cite
Cheng Y, Wang S, Han L, et al. Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget. 2017;8(40):68746-68757doi: 10.18632/oncotarget.19975.
Cheng, Y., Wang, S., Han, L., Liu, P., Li, H., Ren, X., Yu, J., & Hao, X. (2017). Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget, 8(40), 68746-68757. https://doi.org/10.18632/oncotarget.19975
Cheng, Yanan, et al. "Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors." Oncotarget vol. 8,40 (2017): 68746-68757. doi: https://doi.org/10.18632/oncotarget.19975
Cheng Y, Wang S, Han L, Liu P, Li H, Ren X, Yu J, Hao X. Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget. 2017 Aug 07;8(40):68746-68757. doi: 10.18632/oncotarget.19975. eCollection 2017 Sep 15. PMID: 28978153; PMCID: PMC5620293.
Copy Download .nbib Format: NLM
The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles.

Annals of dermatology

Ha JM, Lim CA, Han K, Ha JC, Lee HE, Lee Y, Seo YJ, Kim CD, Lee JH, Im M.
PMID: 28392646
Ann Dermatol. 2017 Apr;29(2):187-193. doi: 10.5021/ad.2017.29.2.187. Epub 2017 Mar 24.

BACKGROUND: Micro-needle patches have been recently used to increase skin permeability, which improves drug delivery, and for cosmetic purposes. However, these patches may often have limited efficacy due to insufficient skin penetration and reduced compliance caused by discomfort.OBJECTIVE: We...

Cite
Ha JM, Lim CA, Han K, et al. The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles. Ann Dermatol. 2017;29(2):187-193doi: 10.5021/ad.2017.29.2.187.
Ha, J. M., Lim, C. A., Han, K., Ha, J. C., Lee, H. E., Lee, Y., Seo, Y. J., Kim, C. D., Lee, J. H., & Im, M. (2017). The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles. Annals of dermatology, 29(2), 187-193. https://doi.org/10.5021/ad.2017.29.2.187
Ha, Jeong-Min, et al. "The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles." Annals of dermatology vol. 29,2 (2017): 187-193. doi: https://doi.org/10.5021/ad.2017.29.2.187
Ha JM, Lim CA, Han K, Ha JC, Lee HE, Lee Y, Seo YJ, Kim CD, Lee JH, Im M. The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles. Ann Dermatol. 2017 Apr;29(2):187-193. doi: 10.5021/ad.2017.29.2.187. Epub 2017 Mar 24. PMID: 28392646; PMCID: PMC5383744.
Copy Download .nbib Format: NLM
Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.

Respiratory medicine case reports

Imakita T, Fujita K, Kanai O, Terashima T, Mio T.
PMID: 28393006
Respir Med Case Rep. 2017 Mar 29;21:52-55. doi: 10.1016/j.rmcr.2017.03.019. eCollection 2017.

We report a rare case of transformation of non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC), without epidermal growth factor receptor (EGFR) gene mutation, during immunotherapy treatment with nivolumab. A 75-year-old man was referred to our...

Cite
Imakita T, Fujita K, Kanai O, et al. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respir Med Case Rep. 2017;21:52-55doi: 10.1016/j.rmcr.2017.03.019.
Imakita, T., Fujita, K., Kanai, O., Terashima, T., & Mio, T. (2017). Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respiratory medicine case reports, 2152-55. https://doi.org/10.1016/j.rmcr.2017.03.019
Imakita, Takuma, et al. "Small cell lung cancer transformation during immunotherapy with nivolumab: A case report." Respiratory medicine case reports vol. 21 (2017): 52-55. doi: https://doi.org/10.1016/j.rmcr.2017.03.019
Imakita T, Fujita K, Kanai O, Terashima T, Mio T. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respir Med Case Rep. 2017 Mar 29;21:52-55. doi: 10.1016/j.rmcr.2017.03.019. eCollection 2017. PMID: 28393006; PMCID: PMC5376266.
Copy Download .nbib Format: NLM
The distinctive nature of adenocarcinoma of the lung.

OncoTargets and therapy

Roviello G.
PMID: 26366094
Onco Targets Ther. 2015 Sep 02;8:2399-406. doi: 10.2147/OTT.S89225. eCollection 2015.

In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib...

Cite
Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther. 2015;8:2399-406doi: 10.2147/OTT.S89225.
Roviello, G. (2015). The distinctive nature of adenocarcinoma of the lung. OncoTargets and therapy, 82399-406. https://doi.org/10.2147/OTT.S89225
Roviello, Giandomenico. "The distinctive nature of adenocarcinoma of the lung." OncoTargets and therapy vol. 8 (2015): 2399-406. doi: https://doi.org/10.2147/OTT.S89225
Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther. 2015 Sep 02;8:2399-406. doi: 10.2147/OTT.S89225. eCollection 2015. PMID: 26366094; PMCID: PMC4562731.
Copy Download .nbib Format: NLM
Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?.

Rare tumors

Immanuel V, Kingsley PA, Negi P, Isaacs R, Grewal SS.
PMID: 28975017
Rare Tumors. 2017 Aug 29;9(2):6552. doi: 10.4081/rt.2017.6552. eCollection 2017 Jul 03.

Malignant gliomas account for 35-45% of primary brain tumors; among these glioblastoma multiforme (GBM) is the most common adult brain tumor constituting approximately 85%. Its incidence is quite less in the pediatric population and treatment of these patients is...

Cite
Immanuel V, Kingsley PA, Negi P, et al. Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?. Rare Tumors. 2017;9(2):6552doi: 10.4081/rt.2017.6552.
Immanuel, V., Kingsley, P. A., Negi, P., Isaacs, R., & Grewal, S. S. (2017). Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?. Rare tumors, 9(2), 6552. https://doi.org/10.4081/rt.2017.6552
Immanuel, Vivek, et al. "Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?." Rare tumors vol. 9,2 (2017): 6552. doi: https://doi.org/10.4081/rt.2017.6552
Immanuel V, Kingsley PA, Negi P, Isaacs R, Grewal SS. Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect?. Rare Tumors. 2017 Aug 29;9(2):6552. doi: 10.4081/rt.2017.6552. eCollection 2017 Jul 03. PMID: 28975017; PMCID: PMC5617915.
Copy Download .nbib Format: NLM
Cell Signaling in Mesothelial Cells by Asbestos: Evidence for the Involvement of Oxidative Stress in the Regulation of the Epidermal Growth Factor Receptor.

Inhalation toxicology

Faux SP, Houghton CE.
PMID: 26368632
Inhal Toxicol. 2000 Jan;12:327-36. doi: 10.1080/08958378.2000.11463242.

Asbestos has been shown to stimulate the mitogen-activated protein kinase signaling cascade after autophosphoryiation of the epidermal growth factor recptor (EGF-R), an event important in regulating the response of cells to extracellular signals. In studies reported here, we have...

Cite
Faux SP, Houghton CE. Cell Signaling in Mesothelial Cells by Asbestos: Evidence for the Involvement of Oxidative Stress in the Regulation of the Epidermal Growth Factor Receptor. Inhal Toxicol. 2000;12:327-36doi: 10.1080/08958378.2000.11463242.
Faux, S. P., & Houghton, C. E. (2000). Cell Signaling in Mesothelial Cells by Asbestos: Evidence for the Involvement of Oxidative Stress in the Regulation of the Epidermal Growth Factor Receptor. Inhalation toxicology, 12327-36. https://doi.org/10.1080/08958378.2000.11463242
Faux, S P, and Houghton, C E. "Cell Signaling in Mesothelial Cells by Asbestos: Evidence for the Involvement of Oxidative Stress in the Regulation of the Epidermal Growth Factor Receptor." Inhalation toxicology vol. 12 (2000): 327-36. doi: https://doi.org/10.1080/08958378.2000.11463242
Faux SP, Houghton CE. Cell Signaling in Mesothelial Cells by Asbestos: Evidence for the Involvement of Oxidative Stress in the Regulation of the Epidermal Growth Factor Receptor. Inhal Toxicol. 2000 Jan;12:327-36. doi: 10.1080/08958378.2000.11463242. PMID: 26368632.
Copy Download .nbib Format: NLM
Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations.

Thoracic cancer

Li R, Lou Y, Zhang Y, Shi C, Xiong L, Gu A, Han B.
PMID: 28920211
Thorac Cancer. 2013 Nov;4(4):433-439. doi: 10.1111/1759-7714.12044.

BACKGROUND: As it is difficult to obtain enough histopathological data for epidermal growth factor receptor (EGFR) gene detection, it is necessary for us to explore how to perform EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with unknown EGFR gene...

Cite
Li R, Lou Y, Zhang Y, et al. Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. Thorac Cancer. 2013;4(4):433-439doi: 10.1111/1759-7714.12044.
Li, R., Lou, Y., Zhang, Y., Shi, C., Xiong, L., Gu, A., & Han, B. (2013). Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. Thoracic cancer, 4(4), 433-439. https://doi.org/10.1111/1759-7714.12044
Li, Rong, et al. "Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations." Thoracic cancer vol. 4,4 (2013): 433-439. doi: https://doi.org/10.1111/1759-7714.12044
Li R, Lou Y, Zhang Y, Shi C, Xiong L, Gu A, Han B. Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations. Thorac Cancer. 2013 Nov;4(4):433-439. doi: 10.1111/1759-7714.12044. PMID: 28920211.
Copy Download .nbib Format: NLM
Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.

Oncology letters

Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, Zhang M, Xing D.
PMID: 28454283
Oncol Lett. 2017 Mar;13(3):1509-1517. doi: 10.3892/ol.2017.5602. Epub 2017 Jan 17.

Hepatocellular carcinoma (HCC) has become a leading cause of cancer-associated mortality worldwide and is thus of great concern. Although various chemotherapeutic drugs are currently used for the treatment of HCC, severe side effects associated with these treatments have prompted...

Cite
Wang X, Ding J, Feng Y, et al. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncol Lett. 2017;13(3):1509-1517doi: 10.3892/ol.2017.5602.
Wang, X., Ding, J., Feng, Y., Weng, L., Zhao, G., Xiang, J., Zhang, M., & Xing, D. (2017). Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncology letters, 13(3), 1509-1517. https://doi.org/10.3892/ol.2017.5602
Wang, Xuan, et al. "Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides." Oncology letters vol. 13,3 (2017): 1509-1517. doi: https://doi.org/10.3892/ol.2017.5602
Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, Zhang M, Xing D. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncol Lett. 2017 Mar;13(3):1509-1517. doi: 10.3892/ol.2017.5602. Epub 2017 Jan 17. PMID: 28454283; PMCID: PMC5403668.
Copy Download .nbib Format: NLM
Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation.

Oncology letters

Li P, Zhou H, Di G, Liu J, Liu Y, Wang Z, Sun Y, Duan H, Sun J.
PMID: 28454294
Oncol Lett. 2017 Mar;13(3):1581-1586. doi: 10.3892/ol.2017.5641. Epub 2017 Jan 25.

Various

Cite
Li P, Zhou H, Di G, et al. Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation. Oncol Lett. 2017;13(3):1581-1586doi: 10.3892/ol.2017.5641.
Li, P., Zhou, H., Di, G., Liu, J., Liu, Y., Wang, Z., Sun, Y., Duan, H., & Sun, J. (2017). Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation. Oncology letters, 13(3), 1581-1586. https://doi.org/10.3892/ol.2017.5641
Li, Pengfei, et al. "Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation." Oncology letters vol. 13,3 (2017): 1581-1586. doi: https://doi.org/10.3892/ol.2017.5641
Li P, Zhou H, Di G, Liu J, Liu Y, Wang Z, Sun Y, Duan H, Sun J. Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation. Oncol Lett. 2017 Mar;13(3):1581-1586. doi: 10.3892/ol.2017.5641. Epub 2017 Jan 25. PMID: 28454294; PMCID: PMC5403177.
Copy Download .nbib Format: NLM
The association of PTEN hypermethylation and breast cancer: a meta-analysis.

OncoTargets and therapy

Luo S, Chen J, Mo X.
PMID: 27672335
Onco Targets Ther. 2016 Sep 12;9:5643-50. doi: 10.2147/OTT.S111684. eCollection 2016.

OBJECTIVE: Phosphatase and tensin homolog (PTEN) deleted on chromosome 10, as a tumor suppressor gene, is crucial for the development of both familial and sporadic breast cancer (BC). The aim of this study was to perform a meta-analysis to...

Cite
Luo S, Chen J, Mo X. The association of PTEN hypermethylation and breast cancer: a meta-analysis. Onco Targets Ther. 2016;9:5643-50doi: 10.2147/OTT.S111684.
Luo, S., Chen, J., & Mo, X. (2016). The association of PTEN hypermethylation and breast cancer: a meta-analysis. OncoTargets and therapy, 95643-50. https://doi.org/10.2147/OTT.S111684
Luo, Shanshan, et al. "The association of PTEN hypermethylation and breast cancer: a meta-analysis." OncoTargets and therapy vol. 9 (2016): 5643-50. doi: https://doi.org/10.2147/OTT.S111684
Luo S, Chen J, Mo X. The association of PTEN hypermethylation and breast cancer: a meta-analysis. Onco Targets Ther. 2016 Sep 12;9:5643-50. doi: 10.2147/OTT.S111684. eCollection 2016. PMID: 27672335; PMCID: PMC5026181.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 9033 entries